Photo of Bishal Gyawali taken from qcri.queensu.ca
Mar 22, 2024, 23:26
Bishal Gyawali: The totality of evidence remains against routine adoption of adjuvant cdk4/6 as the default SOC
Bishal Gyawali, Associate Professor and Medical Oncologist at
“This is a really good summary. Plus informative censoring and other adjuvant Cdk 4/6 trials with equally dubious results. The totality of evidence remains against routine adoption of adjuvant cdk4/6 as the default SOC. We discussed this in detail in our The Lancet Oncology essay, which still remains valid.”
Quoting Mark Bolton’s post:
“NATALEE: A good example of clinically insignificant ~3% benefit in a contrived endpoint at 3-years that jacks up toxicity, plus what happens at ~40 months? Hard to tell without CIs.”
Source: Bishal Gyawali/X and Mark Bolton/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 13:26
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43